Compounded topical preparations (CTP) were used to treat psoriasis until the last century and have disappeared from guidelines. The present authors report two severe psoriasis patients who were treated with CTP. A man had psoriasis with a PASI of 23 and a body surface area (BSA) of 43%. He had been using daily for several weeks a CTP including minoxidil, clobetasol propionate and hydroxyprogesterone formulated in an alcohol based vehicle. A woman suffered from psoriasis with an annular inflammatory pattern and a central healing. The PASI was 20 and the BSA was 30%. She had been using a CTP daily for 4 months including resorcinol, salicylic acid, 0.05% tretinoin cream, bethamethasone dipropionate cream. Until the 1970s, the dermatological textbooks recommended to treat severe psoriasis with CTP. Nowadays, CTP are considered outdated because of the large therapeutic armamentarium. The stability and benefit risks of the CTP used here were not documented. The use of CTP in psoriasis should be regulated and must be evidence based. Strict protocol and stability evaluation for preparations must be confirmed prior to compounding.
| INTRODUCTION
Compounded topical preparations (CTP) were commonly used to treat psoriasis until the end of the last century. They have disappeared from treatment guidelines . The current practice for the treatment of mild to moderate psoriasis is the use of highly potent topical steroids alone or in combination with calcipotriol. When psoriasis affects more than 10% body surface area or if the Psoriasis Area and Severity Index (PASI) is >10, it is advisable to consider systemic treatment, phototherapy (Mason, Mason, Cork, Hancock, & Dooley, 2013; Paul et al., 2010) , biologic or apremilast (Sbidian et al., 2017) .
Adhering to evidenced-based guidelines in practice should improve the quality of patient outcomes (Bricker et al., 2010; Cannon et al., 2011; Duffy, Lynn, Didura, et al., 2008; Marshall, Cartwright, Berry, Stowell, & Miller, 2012) . Several case studies have demonstrated that education, specifically Performance Improvement continuing medical education, improves clinical practice. Resistance to change has been pointed as a common barrier to practice improvement and the application of guidelines. This phenomenon does also affect dermatologist therapeutics practice. The present authors and others have reported that there is a delay in the use of systemic treatment in plaque psoriasis (Maza et al., 2012) . This explains why many patients with extensive psoriasis are still treated with topical agents or remain untreated. The present authors report here two patients with severe chronic psoriasis plaque who were treated with compounded topical preparations containing potentially harmful ingredients. (Maza, 2012) . The compounded formulations used by our patients were not reimbursed by the Health Insurance Authority, these empirical formulations not validated by in vitro studies of compatibility, stability, skin penetration. They were not supported by clinical studies of efficacy and tolerability. In the first case, the alcoholic excipient used could potentially increase the risk of systemic effect of ingredients by promoting skin permeation, the use of Minoxidil, an approved treatment for female pattern hair loss due to his vasodilator effect is totally empirical (Rossi et al., 2012) . There is a lack of evidence based literature to support the use of CTP. Nevertheless, in parallel of the improvement of the knowledge about psoriatic mechanism, novel advances in topical antipsoriatic agents have been made, with the development of new formulations (liposomes and microemulsions) (Agrawal, Gupta, Dube, & Vyas, 2013) 4 | CONCLUSION The use of compounded topical preparations in psoriasis should be strictly regulated and standardized. Physicians should be made aware of the criteria requiring the use of systemic psoriasis treatment instead of topical preparations (Gardinal, Ammoury, & Paul, 2009 ).
| OBSERVATIONS

